Conference Dates
June 12 – 17, 2022
Abstract
The development of novel and/or improved vaccines as well as the establishment of tools to monitor vaccine responses are two key factors to control COVID-19 pandemic, often requiring the manufacturing of significant amounts of high-quality SARS-CoV-2 antigens.
In this work, we produced SARS-CoV-2 Spike (S) and the receptor binding domain (RBD) proteins in human or insect cell lines to be further used in (i) the implementation of serological assays for detection of antibodies against SARS-CoV-2 virus in the Portuguese population, and (ii) the development of a virosome-based COVID-19 vaccine candidate.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Bárbara Fernandes, Rute Castro, Patricia Gomes-Alves, Mario Amacker, Toon Stegmann, Sylvain Fleury, Paula M. Alves, and António Roldão, "Production of high-quality SARS-CoV-2 antigens for vaccine development and serological assays implementation" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/45